Author

Duhyeong Hwang

University of North Carolina at Chapel HillORCID 0000-0002-5650-1643Unclaimed ORCID profile · follow to get notified of new preprints

Biology Disciplines

Click to filter author papers

Cancer Biology· 1 Immunology· 1 Neuroscience· 1

Signature Assays, Organisms & Methods

Click to filter · or open tag

Approach:experimental assay· 3 Organism:mouse· 3 Assay:bulk RNA-seq· 1 Research Focus:cancer & tumor microenvironment· 1 Research Focus:cell signaling & trafficking· 1 Research Focus:cell type annotation· 1 Research Focus:development & morphogenesis· 1 Research Focus:drug response / drug discovery· 1

Frequent Co-Authors

Alexander V. KabanoviD· 3 shared Chaemin LimiD· 3 shared Andrey P. TikunoviD· 2 shared Elias P. RoseniD· 2 shared Marina Sokolsky‐PapkoviD· 2 shared Timothy R. GershoniD· 2 shared Arpan PradhaniD· 1 shared Charles M. PerouiD· 1 shared

Activity by Year

2020-2026 · peak 1/yr

Co-Author Collaboration Network

10 top collaborators · 38 mutual co-author links

Click any collaborator node to inspect or filter shared papers

Focal author (center)Selected co-authorORCID co-authorUnlinked name

Curved chords = mutual co-authorship

3 shared papersCancer Biology

Alexander V. KabanovORCID

Mutual co-authors in cluster

Author profile →

3 papers

Recent·Most cited

Cancer BiologybioRxivPreprintMay 8, 2026

Myeloid compartment reprogramming through nanoparticle delivered resiquimod blocks paracrine growth support and activates phagocytosis to slow tumor progression in endogenous mouse medulloblastoma and diffuse midline glioma models

Leon McSwain, Kyoungtea Kim, Duhyeong Hwang…·Marina Sokolsky‐Papkov

ResiPOx, a nanoparticle-delivered TLR7/8 agonist, reprograms tumor-associated myeloid cells to inhibit tumor growth in mouse models of medulloblastoma and diffuse midline glioma.

DOI 10.64898/2026.04.07.714454

mouserat

𝕏 PostBluesky

ImmunologyBiomaterialsPeer-reviewedAug 8, 2024

Tumor microenvironment immunomodulation by nanoformulated TLR 7/8 agonist and PI3k delta inhibitor enhances therapeutic benefits of radiotherapy

Mostafa Yazdimamaghani, Oleg V. Kolupaev, Chaemin Lim…·Jonathan Stuart Serody

This study shows that combining nanoformulated TLR7/8 agonist and PI3K delta inhibitor with radiotherapy improves anti-tumor activity in TNBC by modulating the tumor microenvironment.

35 citationstop 3%

mousebulk RNA-seq

𝕏 PostBluesky

NeuroscienceNanomedicine Nanotechnology Biology and MedicinePeer-reviewedNov 28, 2020

Poly(2-oxazoline) nanoparticle delivery enhances the therapeutic potential of vismodegib for medulloblastoma by improving CNS pharmacokinetics and reducing systemic toxicity

Duhyeong Hwang, Taylor Dismuke, Andrey P. Tikunov…·Marina Sokolsky‐Papkov

This paper develops a nanoparticle formulation of vismodegib that improves its efficacy for medulloblastoma treatment by enhancing CNS pharmacokinetics and reducing systemic toxicity.

53 citations

mouseexperimental assay

𝕏 PostBluesky